Rapid analysis of amphetamine-type substances using Agilent's QuickProbe gas chromatograph/mass spectrometer technology.

The Agilent QuickProbe gas chromatograph/mass spectrometer (QP-GCMS) is a rapid analytical instrument requiring minimal sample preparation. The instrument was considered for the screening of samples for potential implementation at New Zealand's border screening laboratory. One of the project's primary aims was to validate the method for the analysis of border seizures, including drug concealments, novel psychoactive substances (NPS), low-dose drugs and unknown substances. For the application to be useful beyond the capabilities of current handheld point-of-contact (POC) devices, the initial evaluation has included the analysis of a large variety of compounds in a large variety of matrices. These data will be reported separately. However, during the evaluation, several chromatographical challenges were encountered during the analysis of amphetamine-type substances (ATS). As such, the QP-GCMS required some troubleshooting and method development to improve resolution for this class of compounds.

Trends of clandestine laboratories manufacturing methamphetamine in New Zealand between 2009-2021: Evolution, enforcement, legislative, and COVID-19 effects.

The most common method of domestic methamphetamine manufacture encountered in New Zealand is the hydrogen iodide (HI) reduction of pseudoephedrine/ephedrine. While the overall method used to manufacture methamphetamine has remained consistent, the processes and chemicals utilized have evolved. Understanding the reason for any changes to methamphetamine manufacturing trends can assist jurisdictions with predicting the potential effects of enforcement and legislative initiatives. This paper presents data and trends amassed from suspected clandestine laboratories, associated with the manufacture of methamphetamine, in New Zealand between 2009 and 2021, along with data on methamphetamine, pseudoephedrine, and ephedrine seizures at the border. The data have shown that clandestine manufacturers in New Zealand have evolved the methamphetamine manufacturing process over the years. These changes in trends can largely be attributed to various enforcement and legislative effects and the COVID-19 pandemic response. Effects that enforcement, legislation, and the COVID-19 pandemic response may have had on the precursors, chemicals and equipment encountered are discussed.

Deposition of methamphetamine residues produced by simulated smoking.

In New Zealand, many concerns have been raised over the presence of methamphetamine contamination in households, especially when its provenance is unknown. Previous research found that contamination levels on household surfaces were higher after the premises had been used as a clandestine laboratory. It is believed that the levels of contamination produced from smoking methamphetamine are much less than those produced through manufacture. This study's aim was to determine the amount of methamphetamine contamination produced, after simulated smoking, on a range of common, smooth surface types. Accumulation over time was also investigated. The experiment, comprising four simulated smoking events (referred to as 'smokes') of 0.2 g followed by a fifth simulated smoking event of 1.2 g (a cumulative total of 2 g) of methamphetamine hydrochloride, was carried out in a shipping container. Subsequent swabs were taken from squares of 100 cm2, following the NIOSH 9111 method. Results were quantified using LC-MS/MS. The methamphetamine concentrations measured gave a range from an overall mean of 0.91 µg/100 cm2 after the first smoke and 15.9 µg/100 cm2 after the final smoke. A rate of accumulation for each surface type was established, as well as an order of surfaces showing the most to least observed contamination. A significant reduction in the level of contamination was observed over a short period of time, although a clear rate was not established. Finally, a relationship between the recovered amounts of methamphetamine and amphetamine produced through the pyrolysis (smoking) process was also determined.

Establishing likelihood ratios for evaluating opposing propositions concerning the activity causing methamphetamine contamination: Smoking or manufacture?

In New Zealand, concerns have been raised over the presence of methamphetamine contamination in households, especially when the activity causing the contamination is unknown. The cause of contamination is also a contentious issue in clandestine laboratory cases concerning charges in relation to "Use of Premises" (Section 12: Misuse of Drugs Act 1975, New Zealand). Regardless of the cause, other than scientific opinion, there is currently no analytical technique that can satisfactorily address the provenance of methamphetamine residues. For several years, approximate methamphetamine contamination levels have been collected from suspected clandestine laboratories in New Zealand, where methamphetamine is believed to have been manufactured. This study used this data and compared it to similar data from properties where the drug is suspected to have been used (smoked) to model likelihood ratios (LR). It is well documented that the LR forms the backbone to a Bayesian method of interpreting forensic evidence. As such, this data has the potential to underpin a novel Bayesian approach in the evaluation of clandestine laboratory evidence.